The US Human Organoids Market was valued at $197.6 Million in 2024 and projected to reach to $398.1 Million by 2029, representing a compound annual growth rate of 15.0%. The US human organoids market is positioned for sustained expansion through 2029, driven by increasing adoption in pharmaceutical R&D, regenerative medicine, and precision medicine initiatives.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
The US human organoids market is valued at $197.6 million in 2024, with strong momentum driven by federal research funding and private biotech investment in regenerative medicine applications.
With a 15% CAGR through 2029, the US market is expanding faster than the global average of 14.4%, reflecting the country's leadership in organoid research and commercialization.
The US hosts world-leading academic institutions and biotech companies advancing organoid technology for drug discovery, toxicology testing, and personalized medicine applications.
FDA initiatives and NIH funding programs are accelerating organoid adoption in pharmaceutical development, reducing reliance on animal testing and enabling faster clinical pathways.
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
AstraZeneca researchers acquired an adult stem cell-derived human small intestinal organoid model from the HUB biobank. They used it to evaluate toxicity associated with oral oncology drugs. | Organoid response data were integrated into mathematical models to predict intestinal injury and clinical diarrhea, supporting investigation of drug dosing and schedules. |
|
|
Roche (Genentech) purchased patient-derived colorectal cancer organoids PDM95, PDM96, and PDM2674 from ATCC. | Provided access to established human colorectal cancer models for experimental studies, avoiding the need to derive each model from fresh patient samples. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | DEVELOPMENTAL BIOLOGY (Application) |
| Forecast Period | 2024-2029 |
| Growth Rate | CAGR of 14.4% from 2024 to 2029 |
| Largest Segment | READY-TO-USE PRODUCTS (Type) |
| Market Size Base Year (Billions) | ~USD 1.19 (2024) |
| Revenue Forecast (Billions) | ~USD 2.33 (2029) |
| Segments Covered | Product, Type, Source, Culture Method, Disease Area, Application, End User |
7 segment dimensions are covered across the global market.
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 46.7 | 51.3 | 56.9 | 63.7 | 71.7 | 81.7 | 93.7 | 108.2 | 13.7 |
| CROS | 128.4 | 141.6 | 157.9 | 177.8 | 201.2 | 230.2 | 265.4 | 308.1 | 14.3 |
| OTHER END USERS | 14.6 | 15.8 | 17.4 | 19.3 | 21.5 | 24.2 | 27.5 | 31.4 | 12.6 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 196.2 | 219.1 | 247.3 | 281.7 | 322.7 | 373.5 | 435.5 | 511.5 | 15.6 |
| TOTAL | 385.9 | 427.8 | 479.5 | 542.4 | 617.1 | 709.6 | 822.1 | 959.2 | 14.9 |
The US human organoids market was valued at $197.6 million in 2024 and is projected to reach $398.1 million by 2029.
The US human organoids market is expected to grow at a compound annual growth rate (CAGR) of 15.0% from 2024 to 2029.
Key drivers include advances in stem cell technology, increased pharmaceutical R&D spending, adoption of organoids as alternatives to animal testing, and strong US regulatory support for organoid-based therapeutics.
The US market is being driven by applications in oncology, neurology, organ transplantation, and personalized drug testing, with significant investment from both academic and private biotech sectors.
The US FDA has provided guidance on organoid-based therapeutics and supports their use in drug discovery and disease modeling, creating a favorable regulatory pathway for commercialization and market growth.
The study involved major activities in estimating the current market size for the human organoids market. Exhaustive secondary research was done to collect information on the human organoids industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the human organoids market.
The four steps involved in estimating the market size are
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.
BREAKDOWN OF PRIMARY PARTICIPANTS:

To know about the assumptions considered for the study, download the pdf brochure
Both top-down and bottom-up approaches were used to estimate and validate the human organoids market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
The research methodology used to estimate the market size includes the following:

After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
An organoid is a miniaturized and simplified version of an organ produced in vitro in three dimensions that shows realistic microanatomy. Organoids are derived from one or a few cells from tissue, embryonic stem cells, or induced pluripotent stem cells, which can self-organize in three-dimensional culture owing to their self-renewal and differentiation capacities.
Senior Management
• End User
• Finance/Procurement Department
• R&D Department
MarketsandMarkets offers the following customizations for this market report.
Country Information
Company profiles
Product Analysis
Full forecast, segment splits, and company analysis for all Human Organoids Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report